Several CEOs and 17 years later, Melinta scores an FDA OK for its antibiotic
It’s taken 17 years and a long chain of CEOs, but privately held Melinta Therapeutics has nabbed an FDA approval for its antibiotic delafloxacin, which can now be sold as Baxdela.
Melinta announced a little more than a year ago that the antibiotic had proven non-inferior to vancomycin for acute bacterial skin and skin structure infections (ABSSSI). The last switch up in the executive suite at Melinta, once called Rib-X, was when Mary Szela— now CEO of Novelion — was replaced by R&D chief Eugene Sun in 2015.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.